Core Viewpoint - Eli Lilly announced the acquisition of Orna Therapeutics for up to $2.4 billion, marking a significant move into the in vivo CAR-T therapy space [3][8]. Group 1: Acquisition Details - The acquisition price of $2.4 billion includes both upfront payments and milestone payments related to clinical development [3]. - Orna Therapeutics is recognized as the first company globally to develop new therapies using engineered circRNA [5]. Group 2: Orna Therapeutics' Innovations - Orna is advancing a new therapy that combines engineered circRNA with novel lipid nanoparticles (LNP) to generate CAR-T cells in vivo, targeting diseases such as B-cell driven autoimmune disorders [6]. - The lead project, ORN-252, is a clinical trial-ready in vivo CAR-T therapy targeting CD19 [6]. Group 3: Industry Context - Eli Lilly's acquisition aligns with recent trends in the industry, where companies like Gilead Sciences and AbbVie have also made significant investments in in vivo CAR-T technologies [8]. - The acquisition is part of Eli Lilly's broader strategy to leverage cash flow from GLP-1 weight loss drugs for further investments in innovative therapies [11].

Core Viewpoint - Eli Lilly (LLY.US) has announced a definitive acquisition agreement with Orna Therapeutics to enhance its position in cell therapy and gene medicine, with a potential total payout of up to $2.4 billion to Orna's shareholders [1]. Group 1: Acquisition Details - The acquisition includes a cash payment to Orna's shareholders, which consists of an upfront payment and additional payments contingent upon achieving specific clinical development milestones [1]. - The primary assets being acquired are Orna's circular RNA technology platform and its in vivo CAR-T pipeline, which are expected to strengthen Eli Lilly's capabilities in innovative therapies [1]. Group 2: Technology and Innovation - Orna Therapeutics specializes in engineering circular RNA combined with novel lipid nanoparticle (LNP) delivery systems, allowing patients' bodies to generate therapeutic cells that target the root causes of diseases [1]. - The technology offers advantages such as prolonged expression of therapeutic proteins, addressing limitations currently faced by RNA and cell therapies [1]. Group 3: Key Projects - Orna's flagship project, ORN-252, is a clinical-stage in vivo CAR-T therapy targeting CD19, primarily aimed at treating B-cell mediated autoimmune diseases, which aligns with Eli Lilly's strategic focus [1].

Core Viewpoint - Eli Lilly (LLY.US) has announced a definitive acquisition agreement with Orna Therapeutics to enhance its position in cell therapy and gene drug sectors, with a potential total payout of up to $2.4 billion to Orna's shareholders [1] Group 1: Acquisition Details - Eli Lilly's acquisition of Orna includes a cash payment to shareholders, which may reach up to $2.4 billion, consisting of upfront payments and milestone payments tied to specific clinical development achievements [1] - The acquisition focuses on Orna's circular RNA technology platform and in vivo CAR-T pipeline, which are expected to strengthen Eli Lilly's capabilities in innovative therapies [1] Group 2: Technology and Innovation - Orna specializes in engineering circular RNA combined with novel lipid nanoparticle (LNP) delivery systems, allowing patients' bodies to generate therapeutic cells that target the root causes of diseases [1] - The technology offers advantages such as prolonged expression of therapeutic proteins, addressing limitations in current RNA and cell therapies [1] Group 3: Key Projects - Orna's core project, ORN-252, is a clinically ready in vivo CAR-T therapy targeting CD19, primarily aimed at treating B cell-mediated autoimmune diseases, which aligns with Eli Lilly's strategic focus [1]

Core Insights - Eli Lilly has agreed to acquire Orna Therapeutics, a genetic-medicine biotechnology company, for a total consideration of up to $2.4 billion in cash [1] Company Summary - The acquisition reflects Eli Lilly's strategic focus on expanding its capabilities in genetic medicine [1] - Orna Therapeutics specializes in innovative genetic therapies, which aligns with Eli Lilly's growth objectives in the biotechnology sector [1] Financial Implications - The deal is valued at up to $2.4 billion, indicating a significant investment by Eli Lilly in the biotechnology space [1]

Eli Lilly & Co agreed to buy US biotech Orna Therapeutics for up $2.4 billion in cash in the latest deal by the company best known for its weight-loss drug Zepbound https://t.co/kJW1YHokse ...

Lilly agrees to acquire Orna Therapeutics in an all-cash deal. ...

Eli Lilly will acquire therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said on Monday. ...

Core Viewpoint - The article discusses the evolution and potential of CAR-T cell therapy, particularly focusing on the emerging in vivo CAR-T approach, which aims to simplify the treatment process and reduce costs while maintaining efficacy [2][3][6]. Group 1: Current State of CAR-T Therapy - CAR-T cell therapy has become a leading treatment for various blood cancers, with a projected market size of $11 billion in 2023, expected to grow to $190 billion by 2034 [2]. - The traditional CAR-T therapy process is complex and time-consuming, requiring several weeks for preparation and costing upwards of $500,000, limiting accessibility for many patients [3][4]. Group 2: In Vivo CAR-T Development - In vivo CAR-T therapy aims to generate CAR-T cells directly within the body, significantly simplifying the production process and potentially reducing costs by an order of magnitude [6][7]. - Companies like Capstan Therapeutics and Azalea Therapeutics are at the forefront of developing in vivo CAR-T therapies, with significant investments from major pharmaceutical companies [7]. Group 3: Advantages of In Vivo CAR-T - In vivo CAR-T therapy eliminates the need for pre-treatment chemotherapy, reducing associated side effects and expanding the patient population that can benefit from the treatment [12]. - The risk of severe side effects, such as cytokine release syndrome (CRS), may be lower with in vivo CAR-T compared to traditional ex vivo methods [12]. Group 4: Challenges and Innovations - The delivery of CAR genes to the correct cells in vivo presents challenges, with companies exploring various methods, including targeted lipid nanoparticles and modified viral vectors [10][11]. - Capstan Therapeutics and others are shifting towards using lipid nanoparticles to deliver RNA, which may offer a safer alternative to viral vectors [15]. Group 5: Clinical Trials and Future Outlook - Several in vivo CAR-T therapies are currently in clinical trials, with expectations for increased activity in the field by 2025 and 2026 [19]. - The article highlights the growing interest and competition in the CAR-T space, with many companies striving to make CAR-T therapy more accessible and effective [19].